P Bourdon1, J A Jablonski, B H Chao
1Biogen Inc., Cambridge, MA 02142.
Novel bivalent thrombin inhibitors, called hirulogs, were developed. These hirulogs demonstrate versatile interactions with thrombin, showing improved antithrombin and anticoagulant activities for potential therapeutic applications.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: